Sunday - July 13, 2025
Real-world Data Shows Teclistamab Can Benefit Many Multiple Myeloma Patients Who Would Have Been Ineligible for Pivotal Trial
July 09, 2025
PHILADELPHIA, Pennsylvania, July 9 [Category: Medical] -- The American Association for Cancer Research posted the following news release:

* * *

Real-world Data Shows Teclistamab Can Benefit Many Multiple Myeloma Patients Who Would Have Been Ineligible for Pivotal Trial

*

Retrospective study revealed efficacy of the bispecific T-cell engager in patients with high-risk, heavily pretreated multiple myeloma, including after prior BCMA therapy
. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products